Syndax Pharmaceuticals (SNDX) Competitors $16.13 +0.01 (+0.06%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$16.06 -0.07 (-0.46%) As of 09/3/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNDX vs. NUVL, MRUS, CRSP, CYTK, TGTX, ACAD, KRYS, ADMA, PCVX, and PTCTShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), Cytokinetics (CYTK), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Vaxcyte (PCVX), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Its Competitors Nuvalent Merus CRISPR Therapeutics Cytokinetics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech ADMA Biologics Vaxcyte PTC Therapeutics Nuvalent (NASDAQ:NUVL) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends. Do insiders & institutionals have more ownership in NUVL or SNDX? 97.3% of Nuvalent shares are held by institutional investors. 10.2% of Nuvalent shares are held by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend NUVL or SNDX? Nuvalent currently has a consensus target price of $119.36, indicating a potential upside of 50.07%. Syndax Pharmaceuticals has a consensus target price of $38.00, indicating a potential upside of 135.59%. Given Syndax Pharmaceuticals' higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better valuation & earnings, NUVL or SNDX? Nuvalent has higher earnings, but lower revenue than Syndax Pharmaceuticals. Nuvalent is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-16.23Syndax Pharmaceuticals$23.68M58.68-$318.76M-$3.89-4.15 Does the media favor NUVL or SNDX? In the previous week, Nuvalent had 7 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 18 mentions for Nuvalent and 11 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.46 beat Nuvalent's score of 1.39 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NUVL or SNDX more profitable? Nuvalent has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -428.48%. Nuvalent's return on equity of -32.58% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% Syndax Pharmaceuticals -428.48%-130.47%-56.12% Which has more risk and volatility, NUVL or SNDX? Nuvalent has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. SummaryNuvalent beats Syndax Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41B$3.11B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-4.1521.1082.3726.60Price / Sales58.68368.84504.28161.15Price / CashN/A43.5325.7028.92Price / Book8.818.1310.646.56Net Income-$318.76M-$53.35M$3.28B$266.04M7 Day Performance-1.16%0.73%0.10%-0.89%1 Month Performance55.39%7.76%8.91%4.34%1 Year Performance-17.91%11.97%48.38%24.06% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals4.4227 of 5 stars$16.13+0.1%$38.00+135.6%-21.5%$1.41B$23.68M-4.15110News CoveragePositive NewsNUVLNuvalent3.2307 of 5 stars$75.19-1.2%$118.91+58.1%-4.9%$5.42BN/A-15.3540Positive NewsAnalyst ForecastMRUSMerus3.003 of 5 stars$68.32+1.5%$88.75+29.9%+32.0%$5.15B$56.23M-12.3737News CoveragePositive NewsCRSPCRISPR Therapeutics3.5926 of 5 stars$53.06-0.9%$71.60+35.0%+16.4%$4.82B$35M-9.76460Analyst RevisionCYTKCytokinetics4.1069 of 5 stars$38.99+3.1%$71.58+83.6%-8.4%$4.67B$18.47M-7.65250Trending NewsAnalyst ForecastInsider TradeOptions VolumeTGTXTG Therapeutics4.3251 of 5 stars$28.78+0.7%$46.25+60.7%+40.2%$4.56B$329M77.75290News CoveragePositive NewsACADACADIA Pharmaceuticals4.0432 of 5 stars$26.30-1.0%$28.88+9.8%+57.2%$4.44B$1.02B19.77510Analyst RevisionKRYSKrystal Biotech4.8083 of 5 stars$148.99+0.9%$210.38+41.2%-19.6%$4.30B$290.52M30.22210Positive NewsADMAADMA Biologics3.9279 of 5 stars$17.29+0.2%$27.67+60.0%+2.0%$4.13B$474.17M20.12530Positive NewsPCVXVaxcyte2.7844 of 5 stars$30.81+0.9%$136.50+343.0%-70.9%$4.00BN/A-7.49160News CoveragePositive NewsPTCTPTC Therapeutics3.8467 of 5 stars$50.08+0.6%$69.15+38.1%+66.3%$3.98B$1.76B7.191,410News CoverageAnalyst Forecast Related Companies and Tools Related Companies NUVL Alternatives MRUS Alternatives CRSP Alternatives CYTK Alternatives TGTX Alternatives ACAD Alternatives KRYS Alternatives ADMA Alternatives PCVX Alternatives PTCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNDX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNDX Stock Alerts